{"filings":[{"id":748796,"accession_number":"0001021771-26-000084","cik":1505497,"company_name":"BioRestorative Therapies, Inc.","ticker":"BRTX","form_type":"8-K","filed_at":"2026-05-29T21:07:05+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"BRTX shareholders approve 20x increase in authorized shares; CEO/CFO sign 3-year employment agreements","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Lance Alstodt signed 3-year employment agreement with $600k annual salary, unchanged.","CFO Robert Kristal signed 3-year employment agreement with $350k annual salary, unchanged.","Shareholders approved increase in authorized common shares from 75M to 1.5B (20x).","Vote: 9,868,606 for, 2,389,059 against, 179,207 abstentions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12387461.008316008,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93260,"accession_number":"0001021771-26-000068","cik":1505497,"company_name":"BioRestorative Therapies, Inc.","ticker":"BRTX","form_type":"8-K","filed_at":"2026-05-01T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"BioRestorative Therapies approves 2025 executive bonuses; CEO bonus $300K, VP $287.5K, CFO $140K","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Lance Alstodt awarded $300K cash bonus and $1.5M in option awards; total 2025 compensation $2.4M.","VP Francisco Silva gets $287.5K bonus plus $1.47M in options; total 2025 comp $2.3M.","CFO Robert Kristal awarded $140K bonus and $318K in options; total 2025 comp $801,750.","All bonuses are discretionary for 2025 services, payable in 2026; total compensation up significantly from 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12387461.008316008,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93259,"accession_number":"0001021771-26-000058","cik":1505497,"company_name":"BioRestorative Therapies, Inc.","ticker":"BRTX","form_type":"8-K","filed_at":"2026-04-23T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioRestorative Therapies posts updated corporate presentation; no financial details disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Updated presentation made available on company website on April 23, 2026.","Presentation intended for use at conferences and investor meetings.","No material new financial or operational data provided in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":12387461.008316008,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104733,"accession_number":"0001493152-26-006837","cik":1505497,"company_name":"BioRestorative Therapies, Inc.","ticker":"BRTX","form_type":"8-K","filed_at":"2026-02-17T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"BioRestorative raises $5.0M in public offering of stock and warrants to fund clinical programs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 14.3M shares (or pre-funded warrants) and 14.3M five-year warrants at $0.35/unit closed Feb 13.","Gross proceeds ~$5.0M net of ~7% placement agent fee and expenses.","Proceeds to fund BRTX-100 Phase 2 trial, ThermoStem R&D, biocosmeceuticals platform, and working capital.","Rodman & Renshaw acted as exclusive placement agent; 90-day lockup on new equity issuances."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":12387461.008316008,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121017,"accession_number":"0001021771-25-000148","cik":1505497,"company_name":"BioRestorative Therapies, Inc.","ticker":"BRTX","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"BioRestorative Therapies reports Q3 2025 results; press release content omitted from filing","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Press release dated November 12, 2025, announced Q3 2025 financial results and business update.","Conference call scheduled to discuss results, but no dial-in details specified in the filing.","Full financial figures and operational highlights are not extractable from the provided exhibit text.","No specific revenue, EPS, or segment data available for investor analysis."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":340100.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12387461.008316008,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121016,"accession_number":"0001493152-25-017446","cik":1505497,"company_name":"BioRestorative Therapies, Inc.","ticker":"BRTX","form_type":"8-K","filed_at":"2025-10-08T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"BioRestorative Therapies raises $1.085M in registered direct offering at $1.60/share; warrants at $2.75","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Registered direct offering of 678,125 shares at $1.60/share, gross proceeds $1.085M; closing expected Oct 8, 2025.","Concurrent private placement of warrants for 508,594 shares at $2.75 exercise price, 75% warrant coverage, exercisable after 6 months for 5 years.","Offering priced at $1.60/share, above October 3 close of $1.50.","Net proceeds to fund BRTX-100 clinical trials, ThermoStem R&D, biocosmeceuticals platform, and working capital.","CEO notes participation from largest institutional shareholder and management team."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":12387461.008316008,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137637,"accession_number":"0001021771-25-000131","cik":1505497,"company_name":"BioRestorative Therapies, Inc.","ticker":"BRTX","form_type":"8-K","filed_at":"2025-09-25T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"BioRestorative Therapies shareholders elect directors, approve stock plan amendment, ratify auditor, okay exec pay","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected Francisco Silva (1.59M for) and David Rosa (1.47M for) as Class II directors; ~3.33M broker non-votes.","Approved amendment to 2021 Stock Incentive Plan boosting authorized shares from 6.85M to 9.85M (1.34M for, 289K against).","Ratified CBIZ CPAs as independent auditor for FY2025: 4.72M for, 271K against, 4,864 abstentions.","Advisory vote on executive compensation passed: 1.54M for, 107K against, 19,855 abstentions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":12387461.008316008,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137636,"accession_number":"0001021771-25-000116","cik":1505497,"company_name":"BioRestorative Therapies, Inc.","ticker":"BRTX","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioRestorative Therapies releases updated corporate presentation; no financial details in filing","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Updated investor presentation posted on company website and furnished as Exhibit 99.1.","Presentation may be used at upcoming conferences and investor meetings.","No specific financial or operational updates were disclosed in the filing text."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":12387461.008316008,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137635,"accession_number":"0001021771-25-000113","cik":1505497,"company_name":"BioRestorative Therapies, Inc.","ticker":"BRTX","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"BioRestorative Therapies issues Q2 2025 earnings; no figures in provided excerpt","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Press release dated Aug 12, 2025 announces Q2 financial results and a business update.","Conference call scheduled to discuss the results; details in the press release.","Specific revenue, EPS, and segment data not included in the filing text provided."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.94,"consensus_revenue_estimate":null,"consensus_revenue_actual":328300.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12387461.008316008,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154997,"accession_number":"0001021771-25-000092","cik":1505497,"company_name":"BioRestorative Therapies, Inc.","ticker":"BRTX","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioRestorative presents Phase 2 data for BRTX-100: >50% improvement in pain/function in >70% of subjects","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary blinded data from 36 subjects in Phase 2 trial of BRTX-100 for chronic lumbar disc disease presented at ISSCR 2025.","Over 74% of subjects showed >50% improvement in function (ODI) by week 52; over 72% had >50% pain reduction (VAS).","No serious adverse events or dose-limiting toxicities reported between 26 and 104 weeks at target dose of 40 million cells.","Number of evaluated subjects increased from 15 to 36 since last update; FDA requires >30% improvement thresholds.","CEO Lance Alstodt expressed confidence BRTX-100 can meet or exceed FDA thresholds for function and pain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"market_cap_usd":12387461.008316008,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154996,"accession_number":"0001021771-25-000079","cik":1505497,"company_name":"BioRestorative Therapies, Inc.","ticker":"BRTX","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"BioRestorative Therapies issues Q1 2025 results press release; financial details not available","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Company announced Q1 2025 financial results and business update on May 14, 2025.","Press release references a conference call to discuss results, but specific figures are not included in the filing.","No EPS, revenue, or segment data were disclosed in the submitted Form 8-K exhibits."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.64,"consensus_revenue_estimate":null,"consensus_revenue_actual":25000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":12387461.008316008,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154995,"accession_number":"0001021771-25-000074","cik":1505497,"company_name":"BioRestorative Therapies, Inc.","ticker":"BRTX","form_type":"8-K","filed_at":"2025-04-21T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"BioRestorative Therapies replaces auditor Marcum with CBIZ after Marcum attest business acquired","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Marcum LLP resigned as auditor on April 16, 2025; FY2024 and FY2023 reports unqualified except FY2024 includes going-concern paragraph.","CBIZ CPAs P.C. appointed as new independent registered public accounting firm by Audit Committee on same date.","No disagreements with Marcum on accounting principles or audit scope during past two fiscal years and subsequent interim.","Material weaknesses in internal control over financial reporting persisted in FY2024 and FY2023, as previously disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12387461.008316008,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173511,"accession_number":"0001021771-25-000066","cik":1505497,"company_name":"BioRestorative Therapies, Inc.","ticker":"BRTX","form_type":"8-K","filed_at":"2025-03-27T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"BioRestorative Therapies to release FY2024 results after market close on March 27, 2025, with conference call","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Financial results for year ended Dec 31, 2024 will be released after market close on March 27, 2025.","Management will host a conference call following the release to review results and provide a business update.","Conference call details (dial-in, replay) were not included in the filing; no financial figures provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":12387461.008316008,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173510,"accession_number":"0001021771-25-000031","cik":1505497,"company_name":"BioRestorative Therapies, Inc.","ticker":"BRTX","form_type":"8-K","filed_at":"2025-02-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioRestorative Therapies presents at ORS 2025; VP Silva discusses development programs","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Francisco Silva, VP of R&D, presented at Orthopaedic Research Society 2025 Annual Meeting on Feb 8.","Presentation materials will be posted on company website for 90 days under Scientific Publications.","No financial or clinical results from the presentation disclosed in this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":12387461.008316008,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190498,"accession_number":"0001021771-24-000195","cik":1505497,"company_name":"BioRestorative Therapies, Inc.","ticker":"BRTX","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"BioRestorative Q3 operating loss narrows 26% YoY; BRTX-100 Phase 2 data shows improvement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Q3 2024 operating loss $2.3M vs $3.1M YoY (26% improvement); net loss $1.1M ($0.13/sh).","Cash & equivalents $13.1M, no debt as of Sep 30, 2024.","$230,700 product revenue from Cartessa Aesthetics supply agreement in Q3.","Blinded Phase 2 data: 70% of 10 patients at 26 wks had >30% pain reduction, >30% function increase.","No SAEs or dose-limiting toxicity at 26–52 wks; provisional NYSDOH license for allogeneic processing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12387461.008316008,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190497,"accession_number":"0001021771-24-000190","cik":1505497,"company_name":"BioRestorative Therapies, Inc.","ticker":"BRTX","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioRestorative to present Phase 2 BRTX-100 data at spine symposium; Q3 results call Nov 13","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Additional preliminary 26-52 week blinded data from Phase 2 trial of BRTX-100 for chronic lumbar disc disease to be presented on Nov 13, 2024.","Presentation at Orthopaedic Research Society/Philadelphia Spine Research Society 7th International Spine Research Symposium, Nov 10-14.","Company will host webcasted conference call Nov 13 at 4:30pm ET to review data, Q3 2024 financial results, and provide business update."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":12387461.008316008,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190496,"accession_number":"0001021771-24-000188","cik":1505497,"company_name":"BioRestorative Therapies, Inc.","ticker":"BRTX","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["1.01","1.02","9.01"],"status":"ready","headline":"BioRestorative enters into $3.6M ATM offering agreement with Rodman & Renshaw; terminates prior JonesTrading ATM","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered ATM agreement with Rodman & Renshaw on Nov 6, 2024 for up to $3.6M of common stock.","Agent will receive 3.0% commission on gross sales proceeds; company not obligated to sell any shares.","Prior ATM with JonesTrading terminated on Nov 1, 2024; $622,235 of shares sold under that agreement.","Offering made under existing effective S-3 registration statement filed Feb 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12387461.008316008,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206990,"accession_number":"0001021771-24-000180","cik":1505497,"company_name":"BioRestorative Therapies, Inc.","ticker":"BRTX","form_type":"8-K","filed_at":"2024-09-23T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"BioRestorative shareholders approve doubling of stock incentive plan shares to 6.85M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Class I director Nickolay Kukekov re-elected with 2,050,111 votes for, 135,114 withheld, 2,048,738 broker non-votes.","Amendment to 2021 Stock Incentive Plan approved: 1,647,022 for, 518,921 against, 19,282 abstentions, 2,048,738 broker non-votes. Authorized shares increased from 3,850,000 to 6,850,000.","Marcum LLP ratified as auditor for FY2024: 4,152,145 for, 18,696 against, 63,122 abstentions.","Annual meeting held September 19, 2024; all three proposals passed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.15,"market_cap_usd":12387461.008316008,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206989,"accession_number":"0001021771-24-000166","cik":1505497,"company_name":"BioRestorative Therapies, Inc.","ticker":"BRTX","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"BioRestorative Therapies issues Q2 2024 results press release; specific figures not provided","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Press release announcing Q2 2024 financial results was issued on August 13, 2024.","Press release includes a business update and details for a conference call to discuss results.","No specific financial data (revenue, EPS, etc.) are available from the filing text provided.","The filing serves as a notice that results were released, but exhibit content is missing."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.84,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12387461.008316008,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206988,"accession_number":"0001021771-24-000158","cik":1505497,"company_name":"BioRestorative Therapies, Inc.","ticker":"BRTX","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"BioRestorative Therapies schedules Q2 2024 earnings release and call for Aug 13","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Financial results for Q2 2024 will be released after market close on Tuesday, August 13, 2024.","Management will host a conference call following the release to review results and provide a business update.","Press release announcing the schedule was issued on August 6, 2024.","No financial figures or guidance were provided in this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":12387461.008316008,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224289,"accession_number":"0001021771-24-000142","cik":1505497,"company_name":"BioRestorative Therapies, Inc.","ticker":"BRTX","form_type":"8-K","filed_at":"2024-05-24T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"BioRestorative receives Nasdaq notice for late 10-Q filing; no immediate delisting","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified BioRestorative on May 22, 2024 of non-compliance with Listing Rule 5250(c)(1) due to delinquent Form 10-Q for Q1 2024.","Notice has no immediate effect on trading; company has 60 days to submit a plan to regain compliance.","Nasdaq may grant up to 180 calendar days from the 10-Q due date (Nov 11, 2024) for compliance.","Delay stems from ongoing restatement analysis previously disclosed in the May 24, 2024 Form 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12387461.008316008,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224288,"accession_number":"0001021771-24-000140","cik":1505497,"company_name":"BioRestorative Therapies, Inc.","ticker":"BRTX","form_type":"8-K","filed_at":"2024-05-24T23:59:59+00:00","items":["4.02"],"status":"ready","headline":"BioRestorative Therapies restates financials due to warrant classification error; no cash impact","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Previously issued annual (FY2023) and quarterly (Q1'22–Q3'23) financial statements should no longer be relied upon.","Restatement reclassifies 2,645,000 public warrants ($10 exercise), 1,856,938 private warrants ($10), and 235,970 underwriter warrants ($12.50) from equity to liabilities.","Non-cash adjustments affect balance sheet and fair value changes in operations; no impact on cash, revenue, operating expenses, or loss from operations.","Company plans to file amended 10-K by June 28, 2024, and concurrently file Q1 2024 10-Q.","Audit committee discussed matter with independent auditor Marcum LLP."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12387461.008316008,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}